Nirmatrelvir-ritonavir reduces the risk of hospitalization or death in higher-risk outpatients with COVID-19.

Is it true that Nirmatrelvir-ritonavir reduces the risk of hospitalization or death in higher-risk outpatients with COVID-19?

Partly. A large meta-analysis of cohort studies reports that nirmatrelvir-ritonavir is associated with reduced hospitalization and death, with clinically meaningful absolute benefit in higher-risk outpatients, and a reference source reports an 88% reduction in unvaccinated high-risk patients. However, a randomized trial in vaccinated higher-risk outpatients found no reduction in hospitalization or death, so the evidence covers the claim only in part and is not uniform.

Verdict: CONTESTED PARTIAL · 2 sources for, 1 against · Last checked 3 Oct 2026

The private library was unavailable for some searches in this check. Missing library results are not evidence against the claim.

Nirmatrelvir/ritonavir. (n.d.). en.wikipedia.org. https://en.wikipedia.org/wiki/Nirmatrelvir/ritonavir

CC, B., AD, P., V, H., J, H., NM, R., L, C., G, H., DB, R., DM, L., JF, S., J, B., K, H., ME, P., S, P., J, D., MG, P., NPB, T., P, E., ND, H., & BD, J. (2026). Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk Outpatients.. doi.org. https://doi.org/10.1056/nejmoa2502457

M, E. & P, K. (2026). Effectiveness of Nirmatrelvir/Ritonavir for Outpatients in the Era of Omicron, Vaccination, and Previous Infection: A Meta-analysis.. doi.org. https://doi.org/10.1007/s11606-026-10494-4